Summit Partners Public Asset Management, LLC Agios Pharmaceuticals, Inc. Transaction History
Summit Partners Public Asset Management, LLC
- $2.79 Billion
- Q3 2024
A detailed history of Summit Partners Public Asset Management, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Summit Partners Public Asset Management, LLC holds 101,730 shares of AGIO stock, worth $4.34 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
101,730Holding current value
$4.34 Million% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding AGIO
# of Institutions
232Shares Held
58.1MCall Options Held
403KPut Options Held
469K-
Farallon Capital Management LLC San Francisco, CA5.66MShares$242 Million1.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.55MShares$237 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$207 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.74MShares$159 Million2.8% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.83MShares$121 Million0.01% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $2.34B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...